Nivalis Therapeutics, Inc. (ALPN)
(Delayed Data from NSDQ)
$6.24 USD
-0.08 (-1.27%)
Updated May 3, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ALPN]
Reports for Purchase
Showing records 21 - 40 ( 156 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Optimized Entry and Exit Levels for ALPN 112123
Provider: Stock Traders Daily
Analyst: Research Department
Industry: Medical - Drugs
Industry: Medical - Drugs
3Q23 Results; Building on Recent Clinical Momentum
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Q3 Financials; RUBY-3 Data at ASN Impressive, Ph3 Planned for 2H:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
The IgAN Era Continues, While Xphozah Makes A Splash Ahead Of Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Industry: Medical - Drugs
Industry: Medical - Drugs
RUBY-3 Continues to Shine; Povetacicept Exhibits Initial Efficacy in IgAN
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Dual AANEM ''23 Presentations Give Povetacicept More Polish
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
IgAN See Best in Class Potential; Ph 3 Planned for 2H24; Broad Development Open
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Kidney Week 2023 - Gearing Up For What''s New in Glomerular Disease
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Industry: Medical - Drugs
Povetacicept Finds a Potential New Target in Myasthenia Gravis
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
RUBY-3 Begins to Sparkle With Favorable SMC Review and Enrollment Initiation in Second IgAN Cohort
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
RUBY-3 IgAN Cohort Progresses; Early Data Ahead at ASN
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
2Q23 Results; Steady Progress for RUBY Studies; Price Target Upped to $17
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Q1 Financials; RUBY-3 Initiated, RUBY-1 Updated Data at EULAR
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
1Q23 Results; RUBY Studies Continue to Progress; Preliminary Data By YE23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
The Renal Renaissance - Key Highlights From Wedbush Event
Provider: Wedbush Securities Inc.
Analyst: CHICO L